Patent ID: 11932676
Assignee: KLOTHO THERAPEUTICS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 8:
9. The method of claim 8, wherein the nephrotoxin is selected from the group consisting of:
one or more aminoglycosides, optionally selected from the group consisting of paromomycin, tobramycin, gentamicin, amikacin, kanamycin, and neomycin;
one or more non-steroid anti-inflammatory drugs (NSAIDs), optionally selected from the group consisting of aspirin (acetylsalicylic acid), celecoxib, diclofenac, diflunisal, etodolac, ibuprofen, indomethacin, ketoprofen, ketorolac, nabumetone, naproxen, oxaprozin, piroxicam, salsalate, sulindac, and tolmetin;
one or more anti-microbial agents, optionally selected from the group consisting of penicillin, ampicillin, a cephalosporin, a sulfonamide, ciprofloxacin, vancomycin, a macrolide, a tetracycline, and rifampin;
one or more anti-fungal agents, optionally selected from the group consisting of amphotericin B and flucytosine;
one or more contrast agents, optionally selected from the group consisting of iodinated radiocontrast media, high-osmolality contrast media (HOCM) having an iodine to molecule ratio of about 1.5:1, low-osmolality, nonionic contrast media (LOCM) having an iodine to molecule ratio of about 3:1, and iso-osmolar contrast media (IOCM) having an iodine to molecule ratio of about 6:1;
one or more antiretroviral agents, optionally selected from the group consisting of adefovir, cidofovir, tenofovir, and foscarnet;
one or more cancer therapeutics or chemotherapeutics, optionally selected from the group consisting of cisplatin, carboplatin, oxaliplatin, an alkylating agent, bendamustine, cyclophosphamide, ifosfamide, a nitrosourea, temozolomide, melphalan, an antitumor antibiotic, mitomycin C, bleomycin, an anthracycline, an antimetabolite, capecitabine, hydroxyurea, methotrexate, pemetrexed, pralatrexate, pentostatin, fludarabine, cladribine, gemcitabine, cytarabine, vinca alkaloids, topotecan, etoposide, a taxane, irinotecan, lenalidomide, eribulin, arsenic trioxide, and ixazomib;
one or more bisphosphonates, or derivatives thereof, optionally selected from the group consisting of zoledronate/zoledronic acid, ibandronate, alendronate, alendronate/cholecalciferol, etidronate, risedronate, risedronate calcium carbonate, pamidronate, and tiludronate;
one or more cyclooxygenase-2 (COX-2) inhibitors, optionally selected from the group consisting of valdecoxib, rofecoxib, and celecoxib;
one or more proton pump inhibitors, optionally selected from the group consisting of omeprazole and lansoprazole;
one or more anticonvulsants, optionally selected from the group consisting of phenytoin and valproic acid;
one or more histamine H2 receptor antagonists, optionally selected from the group consisting of nizatidine, ranitidine, famotidine, and cimetidine;
one or more diuretics, optionally selected from the group consisting of pamabrom, mannitol, a carbonic anhydrase inhibitor, a loop diuretic, bumetanide, ethacrynic acid, torsemide, furosemide, a potassium-sparing diuretic, triamterene, spironolactone, amiloride, a thiazide diuretic, indapamide, chlorthalidone, metolazone, methyclothiazide, hydrochlorothiazide, chlorothiazide, bendroflumethiazide, polythiazide, and hydroflumethiazide;
one or more narcotics or opioids, optionally selected from the group consisting of cocaine and heroin;
one or more elements or elemental metals, optionally selected from the group consisting of lithium, gold, copper, and mercury;
one or more direct-acting smooth muscle relaxants or hydralazine;
one or more spasmolytics, optionally selected from the group consisting of carisoprodol, cyclobenzaprine, metaxalone, methocarbamol, diazepam, clonidine, tizanidine, baclofen, dantrolene, an imidazoline compound, a benzodiazepine, and a hydantoin derivative; and
one or more heavy metal toxicity drugs, immunosuppressants, chelating drugs, or (D-) penicillamine.